NorthWest Biotherapeutics Inc (NWBO)

[Horseb4CarT]

I’m pretty sure I remember Dr Liau giving a presentation a number of years ago and including slides about investigating DCVax L + iclc as the placebo, and adding keytruda in the other leg.

At the time I commented that this was very positive for DCVax in that DCVax + iclc appeared to take the position as the new SOC and must have been believed to be the de facto New SOC for purposes of evaluating the keytruda combination against.

We know that DCVax + iclc is more effective than DCVax alone, so why give a patient anything less. Then, does keytruda in combination raise the bar significantly further is the point of the investigation/trial.

DCVax + iclc + other pd1/PDL1 can be evaluated as well, and beyond to combinations of dcvax + iclc + “other” are also fertile ground for investigation.

In all of this, the types of cancer can vary, but the approach may be tumor agnostic and the efficacy against different tumors are to be determined.

Hence the fertile ground for partnering and/or collaborating with multiple entities.

Note that applying Eden closed system devices provide advantages to all these combo treatments as well as other cell based products manufacturing independent of even DCVax.

Imo, The futures so bright we gotta wear shades